secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001558370-23-007875
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix appoints Timothy Coté to board, expands size to six
-------------------------------------------------------------

- Board expanded from 5 to 6; Timothy R. Coté, M.D. appointed as director, term expiring at 2023 annual meeting.
- Dr. Coté granted fully-vested non-qualified stock option for 15,000 shares at $1.42 per share, plus $35,000 annual cash.
- Former FDA OOPD director, implementing Orphan Drug Act; founded Coté Orphan sold to IQVIA for $20M.
- Also CEO of Silk Road Therapeutics; Soligenix recently acquired exclusive option to its PTX topical for Behçet's Disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837023007875/0001558370-23-007875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837023007875/sngx-20230503x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer